connectatherapeutics – CONNECTA Therapeutics

CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026

2 July, 2026

Preclinical data highlight restoration of cognitive, behavioral and synaptic deficits in Fragile X syndrome models Barcelona, Spain – 2 July 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced that...

CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome

10 June, 2026

in Home, News

by connectatherapeutics

Builds on positive Phase I safety data and represents a key value-inflection milestone for the Company Advances a potentially disease-modifying approach for fragile X syndrome, a condition with no approved targeted therapies Barcelona, Spain – 10 June 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class...

CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support

9 September, 2025

in Home, News

by connectatherapeutics

CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patients CONNECTA leads innovation in neurodevelopmental therapies as a unique European biotech...

CONNECTA Therapeutics announces positive results from Phase I study of neurodevelopmental disorders drug candidate, CTH120

4 March, 2025

in Home, News

by connectatherapeutics

CONNECTA Therapeutics has announced positive results from its Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics profile of its drug candidate CTH120 in adult volunteers. CTH120 is an investigational drug that modulates neuroplasticity, a property of the brain affected in many neurodevelopmental disorders,...

CONNECTA Therapeutics selected for funding under the EIC Accelerator

18 February, 2025

in FRAXCURE, Home, News

by connectatherapeutics

The European Innovation Council (EIC) announced yesterday that CONNECTA Therapeutics has been selected for grant and equity funding, following the last EIC Accelerator cut-off. CONNECTA Therapeutics is honored to be part of the 71 European companies selected among 1211 submitted proposals in the most competitive funding round so...

CONNECTA Therapeutics, CRG, Hospital del Mar Research Institute and I3PT receive €2.7 million from the Spanish Ministry of Science and Innovation to begin Phase IIa trials for CTH120 in Fragile X syndrome

12 February, 2024

in Home, News

by connectatherapeutics

The Phase IIa study will assess the efficacy of CTH120 as an innovative therapy in adults with FXS, the most common form of inherited intellectual disability without a specific treatment. María Martínez, Jordi Fàbrega, Mara Dierssen, Ana Aldea, Rafael de la Torre and Ana Roche representing CONNECTA...

CONNECTA Therapeutics begins administration of CTH120 to the first healthy volunteers in Phase I clinical trial

20 July, 2023

in Home, News

by connectatherapeutics

Hospital del Mar Research Institute CONNECTA Therapeutics announces that the first healthy volunteers in the Phase I clinical trial of CTH120 have been administered the drug at Hospital del Mar - Hospital del Mar Research Institute in Barcelona. The study is recruiting 68 healthy individuals, both women and men aged between 18 and 55 years,...

Connecta Therapeutics starts clinical trials for its Fragile X syndrome drug

6 June, 2023

in Home, News

by connectatherapeutics

This Phase I clinical trial will assess the safety and tolerability of CTH120, which acts as a neuroplasticity modulator. CTH120 has shown very promising results in preclinical studies carried out at Dr Mara Dierssen research lab at the Centre for Genomic Regulation in Barcelona. The study will...

Connecta Therapeutics receives funding to expand therapeutic indications for its FXS drug CTH120

3 February, 2022

in Home, News

by connectatherapeutics

Connecta Therapeutics, a biotechnology company that specialises in the discovery and development of new treatments for unmet central nervous system (CNS) needs, has been granted €247,577 in funding through the Neotec programme, managed by the Spanish Ministry of Science and Innovation Centre for the Development...

Connecta Therapeutics drug for fragile X syndrome receives orphan designation from European Medicines Agency

7 September, 2021

in Home, News

by connectatherapeutics

Barcelona, 06 September 2021 CTH120, designed using artificial intelligence techniques, will start Phase I in 2022 CTH120 designation as orphan drug validates and empowers Connecta Therapeutics's strategy in neurodevelopmental diseases CTH120 Connecta Therapeutics has received approval as orphan drug from the European Medicines Agency (EMA) to treat fragile...

Author: connectatherapeutics